Health 2.0 Europe: Over 35 Speakers from 15 Countries Already Confirmed

27 - 28 October 2011, Berlin, Germany.
Following the success of our first event in Paris in April 2010, the 2nd annual Health 2.0 Europe to hip Berlin. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offering. The 2nd edition will reconvene all the leaders and stakeholders in web 2.0 for health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

Health investor Esther Dyson to present on 'From Health to Wellness 2.0'
An active investor in technology start-ups with a keen interest in the potential of internet technology to change healthcare, Esther Dyson from EDventure Holdings will present on 'From Health to Wellness 2.0'. Her health technology investments include Medstory, sold to Microsoft in 2007, 23andMe, Habit Labs, Medscape, OrganizedWisdom, PatientsLikeMe and ReliefInsite.

Over 35 speakers already confirmed
Confirmed speakers also include:

  • Roberto ASCIONE, Publicis Healthware International, Italy
  • Alberto SANNA, Fondazione Centro San Raffaele, Italy
  • Gábor GYARMATI, Szinapszis Group, Hungary
  • Anna GYARMATI, KamaszPanasz, Hungary
  • Emma STANTON, Department of Health, UK
  • Chris COOPER, EPG Health Media, UK
  • Matt JAMESON EVANS, HealthUnlocked, UK
  • Tim RINGROSE, Networks in Health/Doctors.net.uk, UK,
  • Howard LAST, Active Medicine Ltd, UK
  • Jonathan BLOOR, DocCom, UK
  • Anatole MENON-JOHANSSON, SXT Health CIC, UK
  • Frank ANTWERPES, DocCheck, Germany
  • Michael ALVERS, Transinsight GmbH, Germany
  • Britta LANG, Cochrane Collaboration, Germany
  • Jorge Juan FERNANDEZ, Hospital Sant Joan de Déu, Spain
  • Frederic LLORDACHS, Doctoralia, Spain
  • Miguel CABRER, Medting, Spain
  • Bartho HENGST, KWF Kankerbestrijding, The Netherlands
  • René SIELHORST, Intenz, The Netherlands
  • Joris MOOLENAAR, IPPZ, The Netherlands
  • Robert HALKES, Drimpy, The Netherlands
  • Jasper TEN DAM, my Jellinek, The Netherlands
  • Marco VITULA, Diagnosia, Austria
  • Stephen COOK, 23 Gears Web Systems, Sweden
  • Anna OMSTEDT LINDGREN, MedUniverse, Sweden
  • Greg BIGGERS, Genomera, US
  • Pablo GRAIVER, TrialReach, UK/Israel
  • Dennis VAN ROOIJ, medCrowd, UK/The Netherlands
  • Laurent COUSSIRAT, The Mood Institute, France
  • Ulrich SCHULZE-ALTHOFF, Medisana Space Technologies GmbH, Germany
  • Roman SCHENK, Protegia GmbH, Germany
  • Rachel IREDALE, Cancer Genetics Story Bank, UK
  • Wouter TUIL, MijnZorgnet, NL
  • Roman RITTWEGER, Advisors in Healthcare
  • David Clifford, PatientsLikeMe, USA
  • Kai Sostmann, Charité University Hospital, Germany
  • Topi Hanhela, Pharmaceutical Information Centre, Finland

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Observational study identifies drug that improves …

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,0...

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Roche and Regeneron collaborate to significantly i…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Regeneron (NASDAQ: REGN) announced are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Pfizer and BioNTech share positive early data on l…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vac...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...